Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus.

Troldborg A, Steffensen R, Trendelenburg M, Hauser T, Winther KG, Hansen AG, Stengaard-Pedersen K, Voss A, Thiel S.

J Clin Immunol. 2019 May;39(4):421-429. doi: 10.1007/s10875-019-00627-2. Epub 2019 May 1.

PMID:
31044336
2.

Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.

Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg B, Hetland ML, Ørnbjerg LM, Glinatsi D, Møller J, Boesen M, Christensen R, Stengaard-Pedersen K, Madsen OR, Jensen B, Villadsen JA, Hauge EM, Bennett P, Hendricks O, Asmussen K, Kowalski M, Lindegaard H, Nielsen SM, Bliddal H, Krogh NS, Ellingsen T, Nielsen AH, Balding L, Jurik AG, Thomsen HS, Østergaard M.

JAMA. 2019 Feb 5;321(5):461-472. doi: 10.1001/jama.2018.21362.

PMID:
30721294
3.

Positive predictive value of first-time rheumatoid arthritis diagnoses and their serological subtypes in the Danish National Patient Registry.

Linauskas A, Overvad K, Johansen MB, Stengaard-Pedersen K, de Thurah A.

Clin Epidemiol. 2018 Nov 21;10:1709-1720. doi: 10.2147/CLEP.S175406. eCollection 2018.

4.

Anti-cyclic citrullinated peptide antibodies, 28-joint Disease Activity Score, and magnetic resonance imaging bone oedema at baseline predict 11 years' functional and radiographic outcome in early rheumatoid arthritis.

Hetland ML, Østergaard M, Stengaard-Pedersen K, Junker P, Ejbjerg B, Jacobsen S, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Krogh NS, Hørslev-Petersen K; and The CIMESTRA Study Group*.

Scand J Rheumatol. 2019 Jan;48(1):1-8. doi: 10.1080/03009742.2018.1466362. Epub 2018 Aug 13.

PMID:
30101636
5.

The D-vitamin metabolite 1,25(OH)2 D in serum is associated with disease activity and Anti-Citrullinated Protein Antibodies in active and treatment naïve, early Rheumatoid Arthritis Patients.

Herly M, Stengaard-Pedersen K, Vestergaard P, Østergaard M, Junker P, Hetland ML, Hørslev-Petersen K, Ellingsen T.

Scand J Immunol. 2018 Sep;88(3):e12704. doi: 10.1111/sji.12704. Epub 2018 Aug 22.

PMID:
30048002
6.

Helicobacter pylori infection is not associated with rheumatoid arthritis.

Bartels LE, Pedersen AB, Kristensen NR, Jepsen P, Vilstrup H, Stengaard-Pedersen K, Dahlerup JF.

Scand J Rheumatol. 2019 Jan;48(1):24-31. doi: 10.1080/03009742.2018.1464205. Epub 2018 Jul 17.

PMID:
30014755
7.

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.

Brahe CH, Østergaard M, Johansen JS, Defranoux N, Wang X, Bolce R, Sasso EH, Ørnbjerg LM, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll C, Jørgensen A, Krintel SB, Raun J, Hetland ML.

Scand J Rheumatol. 2019 Jan;48(1):9-16. doi: 10.1080/03009742.2018.1464206. Epub 2018 Jul 9.

PMID:
29985080
8.

Body Fat Percentage, Waist Circumference, and Obesity As Risk Factors for Rheumatoid Arthritis: A Danish Cohort Study.

Linauskas A, Overvad K, Symmons D, Johansen MB, Stengaard-Pedersen K, de Thurah A.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):777-786. doi: 10.1002/acr.23694. Epub 2019 Apr 23.

PMID:
29975015
9.

Corrigendum to "A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of 7 day buprenorphine transdermal patch in osteoarthritis patients naïve to potent-opioids" [Scandinavian Journal of Pain 1 (2010) 122-141].

Breivik H, Ljosaa TM, Stengaard-Pedersen K, Persson J, Aro H, Villumsen J, Tvinnemose D.

Scand J Pain. 2010 Oct 1;1(4):235. doi: 10.1016/j.sjpain.2010.10.001. No abstract available.

PMID:
29913985
10.

A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids.

Breivik H, Ljosaa TM, Stengaard-Pedersen K, Persson J, Aro H, Villumsen J, Tvinnemose D.

Scand J Pain. 2010 Jul 1;1(3):122-141. doi: 10.1016/j.sjpain.2010.05.035. Erratum in: Scand J Pain. 2017 Dec 29;1(4):235.

PMID:
29913983
11.

The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus.

Troldborg A, Thiel S, Trendelenburg M, Friebus-Kardash J, Nehring J, Steffensen R, Hansen SWK, Laska MJ, Deleuran B, Jensenius JC, Voss A, Stengaard-Pedersen K.

J Rheumatol. 2018 Aug;45(8):1136-1144. doi: 10.3899/jrheum.171033. Epub 2018 Jun 15.

PMID:
29907670
12.

The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.

Troldborg A, Jensen L, Deleuran B, Stengaard-Pedersen K, Thiel S, Jensenius JC.

Front Immunol. 2018 Mar 26;9:581. doi: 10.3389/fimmu.2018.00581. eCollection 2018.

13.

Immunomodulating peptides derived from different human endogenous retroviruses (HERVs) show dissimilar impact on pathogenesis of a multiple sclerosis animal disease model.

Bahrami S, Gryz EA, Graversen JH, Troldborg A, Stengaard Pedersen K, Laska MJ.

Clin Immunol. 2018 Jun;191:37-43. doi: 10.1016/j.clim.2018.03.007. Epub 2018 Mar 19.

PMID:
29567431
14.

Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.

Brahe CH, Dehlendorff C, Østergaard M, Johansen JS, Ørnbjerg LM, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Lindegaard H, Hansen I, Lottenburger T, Jacobsen S, Jurik AG, Hetland ML.

Scand J Rheumatol. 2018 Jul;47(4):259-269. doi: 10.1080/03009742.2017.1376107. Epub 2018 Jan 16.

PMID:
29336711
15.

Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate.

Nielsen UB, Bruhn LV, Ellingsen T, Stengaard-Pedersen K, Hornung N.

Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):62-67. doi: 10.1080/00365513.2017.1413591. Epub 2017 Dec 11.

PMID:
29228799
16.

Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.

Sode J, Krintel SB, Carlsen AL, Hetland ML, Johansen JS, Hørslev-Petersen K, Stengaard-Pedersen K, Ellingsen T, Burton M, Junker P, Østergaard M, Heegaard NHH.

J Rheumatol. 2018 Jan;45(1):53-61. doi: 10.3899/jrheum.170266. Epub 2017 Nov 15.

PMID:
29142030
17.

Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity.

Issa SF, Christensen AF, Lindegaard HM, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K, Ejbjerg BJ, Lottenburger T, Ellingsen T, Pedersen JK, Junker K, Svendsen A, Tarp U, Østergaard M, Junker P.

Scand J Immunol. 2017 Dec;86(6):471-478. doi: 10.1111/sji.12619. Epub 2017 Nov 1.

18.

Local bone loss in patients with anti-citrullinated peptide antibody and arthralgia, evaluated with high-resolution peripheral quantitative computed tomography.

Keller KK, Thomsen JS, Stengaard-Pedersen K, Nielsen AW, Schiøttz-Christensen B, Svendsen L, Graakjær M, Petersen PM, Unger B, Kjær SG, Langdahl BL, Hauge EM.

Scand J Rheumatol. 2018 Mar;47(2):110-116. doi: 10.1080/03009742.2017.1333629. Epub 2017 Aug 23.

PMID:
28832223
19.

Vagal influences in rheumatoid arthritis.

Rasmussen SE, Pfeiffer-Jensen M, Drewes AM, Farmer AD, Deleuran BW, Stengaard-Pedersen K, Brock B, Brock C.

Scand J Rheumatol. 2018 Jan;47(1):1-11. doi: 10.1080/03009742.2017.1314001. Epub 2017 Aug 2. Review.

PMID:
28766392
20.

Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.

Glinatsi D, Baker JF, Hetland ML, Hørslev-Petersen K, Ejbjerg BJ, Stengaard-Pedersen K, Junker P, Ellingsen T, Lindegaard HM, Hansen I, Lottenburger T, Møller JM, Ørnbjerg L, Vestergaard A, Jurik AG, Thomsen HS, Torfing T, Møller-Bisgaard S, Axelsen MB, Østergaard M.

Ann Rheum Dis. 2017 Oct;76(10):1707-1715. doi: 10.1136/annrheumdis-2017-211315. Epub 2017 Jun 13.

PMID:
28611080
21.

Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.

Heftdal LD, Stengaard-Pedersen K, Ørnbjerg LM, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B, Møller HJ, Greisen SR.

Scand J Clin Lab Invest. 2017 Sep;77(5):385-389. doi: 10.1080/00365513.2017.1331462. Epub 2017 Jun 9.

PMID:
28598681
22.

Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial.

de Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NHI, Pfeiffer-Jensen M, Laurberg TB, Tarp U, Lomborg K, Maribo T.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):353-360. doi: 10.1002/acr.23280. Epub 2018 Jan 23.

23.

Hepcidin plasma levels are not associated with changes in haemoglobin in early rheumatoid arthritis patients.

Østgård RD, Glerup H, Jurik AG, Kragstrup TW, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Deleuran BW.

Scand J Rheumatol. 2017 Nov;46(6):441-445. doi: 10.1080/03009742.2017.1286382. Epub 2017 May 9.

PMID:
28482738
24.

Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-record evaluated outcomes.

Herly M, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Christensen R, Løgstrup BB, Vestergaard P, Pødenphant J, Junker P, Ellingsen T.

BMJ Open. 2017 Apr 8;7(4):e014816. doi: 10.1136/bmjopen-2016-014816.

25.

Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.

Kristensen AM, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Höllsberg P, Deleuran B, Hvid M.

Cytokine. 2017 Aug;96:1-7. doi: 10.1016/j.cyto.2017.02.017. Epub 2017 Mar 6.

PMID:
28267648
26.

Lectin complement pathway proteins in healthy individuals.

Troldborg A, Hansen A, Hansen SW, Jensenius JC, Stengaard-Pedersen K, Thiel S.

Clin Exp Immunol. 2017 Apr;188(1):138-147. doi: 10.1111/cei.12909. Epub 2017 Jan 18.

27.

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.

Ørnbjerg LM, Østergaard M, Jensen T, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Hetland ML; OPERA Study Group, Slot O, Nielsen LK, Skjødt H, Majgaard O, Lorenzen T, Horn HC, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H.

Clin Rheumatol. 2017 Apr;36(4):781-789. doi: 10.1007/s10067-016-3489-1. Epub 2016 Dec 5.

PMID:
27921185
28.

Effects of maternal health anxiety on children's health complaints, emotional symptoms, and quality of life.

Thorgaard MV, Frostholm L, Walker LS, Stengaard-Pedersen K, Karlsson MM, Jensen JS, Fink P, Rask CU.

Eur Child Adolesc Psychiatry. 2017 May;26(5):591-601. doi: 10.1007/s00787-016-0927-1. Epub 2016 Dec 1.

PMID:
27909834
29.

Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA).

Møller-Bisgaard S, Ejbjerg BJ, Eshed I, Hørslev-Petersen K, Hetland ML, Jurik AG, Thomsen H, Torfing T, Stengaard-Pedersen K, Junker P, Krogh NS, Lottenburger T, Ellingsen T, Andersen LS, Skjødt H, Svendsen AJ, Tarp U, Hansen IT, Pødenphant J, Pedersen JK, Lindegaard H, Hanson LG, Vestergaard A, Glinatsi D, Østergaard M.

Scand J Rheumatol. 2017 Sep;46(5):335-345. doi: 10.1080/03009742.2016.1209550. Epub 2016 Oct 24.

PMID:
27775461
30.

Human Endogenous Retroviral Genetic Element With Immunosuppressive Activity in Both Human Autoimmune Diseases and Experimental Arthritis.

Laska MJ, Troldborg A, Hauge EM, Bahrami S, Stengaard-Pedersen K.

Arthritis Rheumatol. 2017 Feb;69(2):398-409. doi: 10.1002/art.39867.

31.

A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.

Nielsen MA, Andersen T, Etzerodt A, Kragstrup TW, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Moestrup SK, Deleuran B.

Rheumatology (Oxford). 2016 Oct;55(10):1871-9. doi: 10.1093/rheumatology/kew237. Epub 2016 Jun 21.

PMID:
27330157
32.

The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.

Kragstrup TW, Greisen SR, Nielsen MA, Rhodes C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Vorup-Jensen T, Robinson WH, Sokolove J, Deleuran B.

Arthritis Res Ther. 2016 Mar 11;18:61. doi: 10.1186/s13075-016-0964-7.

33.

Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response.

Kragstrup TW, Jalilian B, Keller KK, Zhang X, Laustsen JK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hauge EM, Hvid M, Vorup-Jensen T, Deleuran B.

PLoS One. 2016 Feb 5;11(2):e0148486. doi: 10.1371/journal.pone.0148486. eCollection 2016.

34.

Back pain was less explained than leg pain: a cross-sectional study using magnetic resonance imaging in low back pain patients with and without radiculopathy.

Jensen OK, Nielsen CV, Sørensen JS, Stengaard-Pedersen K.

BMC Musculoskelet Disord. 2015 Dec 3;16:374. doi: 10.1186/s12891-015-0827-4.

35.

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).

Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K; OPERA Study-Group.

Ann Rheum Dis. 2016 Sep;75(9):1645-53. doi: 10.1136/annrheumdis-2015-208166. Epub 2015 Oct 21.

PMID:
26489704
36.

Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Troldborg A, Thiel S, Jensen L, Hansen S, Laska MJ, Deleuran B, Jensenius JC, Stengaard-Pedersen K.

Clin Exp Immunol. 2015 Nov;182(2):132-8. doi: 10.1111/cei.12678. Epub 2015 Aug 31.

37.

Methotrexate utilization in Rheumatoid arthritis. A register-based cohort-study of treatment re-starts after gabs of at least 90 days.

de Thurah A, Nørgaard M, Stengaard-Pedersen K.

Springerplus. 2015 May 15;4:227. doi: 10.1186/s40064-015-0975-x. eCollection 2015.

38.

Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990-2010.

Jakobsen IM, Helmig RB, Stengaard-Pedersen K.

Scand J Rheumatol. 2015;44(5):377-84. doi: 10.3109/03009742.2015.1013982. Epub 2015 Jun 19.

PMID:
26087812
39.

Interleukin-23 in early disease development in rheumatoid arthritis.

Andersen T, Hvid M, Johansen C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B.

Scand J Rheumatol. 2015;44(6):438-42.

PMID:
26087654
40.

Subchondral bone turnover, but not bone volume, is increased in early stage osteoarthritic lesions in the human hip joint.

Klose-Jensen R, Hartlev LB, Boel LWT, Laursen MB, Stengaard-Pedersen K, Keller KK, Hauge EM.

Osteoarthritis Cartilage. 2015 Dec;23(12):2167-2173. doi: 10.1016/j.joca.2015.06.001. Epub 2015 Jun 11.

41.

Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus.

Rasmussen TK, Andersen T, Bak RO, Yiu G, Sørensen CM, Stengaard-Pedersen K, Mikkelsen JG, Utz PJ, Holm CK, Deleuran B.

Arthritis Res Ther. 2015 Jun 9;17:154. doi: 10.1186/s13075-015-0660-z.

42.

Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.

Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):498-502. Epub 2015 May 11.

PMID:
25962601
43.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.

Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Stengaard-Pedersen K, Johansen JS.

Pharmacogenomics J. 2016 Apr;16(2):141-6. doi: 10.1038/tpj.2015.30. Epub 2015 May 5.

PMID:
25939484
44.

Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.

Møller-Bisgaard S, Hørslev-Petersen K, Ejbjerg BJ, Boesen M, Hetland ML, Christensen R, Møller J, Krogh NS, Stengaard-Pedersen K, Østergaard M.

Trials. 2015 Apr 21;16:178. doi: 10.1186/s13063-015-0693-2.

45.

Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus.

Troldborg A, Thiel S, Laska MJ, Deleuran B, Jensenius JC, Stengaard-Pedersen K.

J Rheumatol. 2015 Jun;42(6):948-51. doi: 10.3899/jrheum.141163. Epub 2015 Apr 15.

PMID:
25877499
46.

[No evidence that diet has any influence on the aetiology of rheumatoid arthritis].

Linauskas A, de Thurah A, Andersen GN, Stengaard-Pedersen K.

Ugeskr Laeger. 2015 Apr 13;177(16):V08140445. Review. Danish.

PMID:
25872674
47.

Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument.

Maribo T, de Thurah A, Stengaard-Pedersen K.

Clin Rheumatol. 2016 Apr;35(4):1053-8. doi: 10.1007/s10067-014-2848-z. Epub 2015 Jan 13.

PMID:
25758657
48.

Patient self-assessment of flare in rheumatoid arthritis: criterion and concurrent validity of the Flare instrument.

de Thurah A, Maribo T, Stengaard-Pedersen K.

Clin Rheumatol. 2016 Feb;35(2):467-71. doi: 10.1007/s10067-014-2849-y. Epub 2014 Dec 18.

PMID:
25519219
49.

CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients.

Ammitzbøll CG, Steffensen R, Bøgsted M, Hørslev-Petersen K, Hetland ML, Junker P, Johansen JS, Pødenphant J, Østergaard M, Ellingsen T, Stengaard-Pedersen K.

Arthritis Res Ther. 2014 Oct 31;16(5):475. doi: 10.1186/s13075-014-0475-3.

50.

Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis.

Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, Hørslev-Petersen K, Hetland ML, Østergaard M, Junker P, Hvid M, Deleuran B.

Arthritis Res Ther. 2014 Oct 30;16(5):474. doi: 10.1186/s13075-014-0474-4.

Supplemental Content

Loading ...
Support Center